SLC6A19 and neoplasm: Considering the findings that MYH14 and SLC6A19 can impact TME progression through epigenetic regulation, targeting these signaling pathways may offer a dual strategy to disrupt the dynamics of tumor stem cells and epigenetic regulation within the TME, thereby delaying tumor progression.